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In this study, we investigated whether IFNk3 and IL-3 reciprocally influence their capacity to activate
various functions of human plasmacytoid dendritic cells (pDCs). In fact, we preliminarily observed that
IFNk3 upregulates the expression of the IL-3Ra (CD123), while IL-3 augments the expression of
IFNkR1 in pDCs. As a result, we found that combination of IFNk3 and IL-3 induces a strong potentiation
in the production of TNFa, IFNa, as well as in the expression of Interferon-Stimulated Gene (ISG) mRNAs
by pDCs, as compared to either IFNk3 or IL-3 alone. In such regard, we found that endogenous IFNa
autocrinally promotes the expression of ISG mRNAs in IL-3-, but not in IFNk3 plus IL-3-, treated pDCs.
Moreover, we uncovered that the production of IFNa by IFNk3 plus IL-3-treated pDCs is mostly depen-
dent on endogenously produced TNFa. Altogether, our data demonstrate that IFNk3 and IL-3 collaborate
to promote, at maximal levels, discrete functional responses of human pDCs.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
Type III interferons (IFNs)/IFNks include four members, namely
IFNk1, IFNk2, IFNk3 and the more recently identified IFNk4 [1,2],
that share functional similarities with type I IFNs (IFNa and IFNb),
in particular a direct anti-viral effect [1,3]. In fact, IFNks and type I
IFNs, via the Jak-STAT signaling pathway, trigger the transcrip-
tional activation of hundreds of Interferon-Stimulated Genes
(ISGs), which, ultimately, are responsible for the antiviral and
immune IFN-mediated effect [3,4]. On the other hand, a difference
between the two IFN families relies on the composition and distri-
bution of their receptors. Accordingly, type I IFN signal through a
heterodimeric receptor, composed by IFNaR1 and IFNaR2
subunits, widely distributed in most cell types, including all
leukocytes subpopulations [5]. By contrast, IFNks signal through
a heterodimeric receptor complex composed of IL10R2 and a speci-
fic IFNkR1 [6,7]: while IL10R2 is ubiquitously expressed, IFNkR1displays a restricted tissue expression that is limited to epithelial
cells such hepatocytes or cells of the respiratory, gastrointestinal
and reproductive tracts, as well as to discrete leukocyte popula-
tions, including plasmacytoid DCs (pDCs) and B cells [8–10].
Among IFNkR1-expressing cells, pDCs represent a unique DC
subset specialized in the promotion of the early phase of antiviral
immune responses, given their ability to produce high amounts of
IFNa and several inflammatory cytokines and chemokines in
response to viruses/viral components [11]. Recently, we reported
that human pDCs incubated with IFNk3 prolong their survival,
alter the expression of CD83, CD86, CD62L and HLA-DR and pro-
duce variable amounts of IFNa, CXCL10 and TNFa [12], extending
previous observations on the effects of IFNks on pDCs [9,10]. We
also observed that IFNk3 upregulates the expression of the
IL-3Ra/CD123 [12], suggesting that, by this mechanism, IFNk3
might modulate pDC responsiveness to IL-3. The latter cytokine
functions as both a hematopoietic growth factor and a regulator
of cell differentiation [13], and can be secreted by activated T cells,
endothelial cells and mast cells under inflammatory conditions
[13–15], or even detected in the tumor microenvironment [16].
pDCs, given their constitutive expression of both CD123 and
IL-3Rb/CD131 [13,17], are known to respond to IL-3, for instance
in terms of survival and differentiation into mature DCs with
increased expression of MHC-I and -II and co-stimulatory
molecules [17,18], as well as of production of TNFa [18,19].
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IFNk3 and IL-3 may cooperate in influencing discrete functions of
human pDCs.2. Materials and methods
2.1. Isolation and culture of pDCs
pDCs were purified from PBMCs using the BDCA-4 Diamond
Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Purity
of isolated pDCs (>98%) was determined by flow cytometry
analysis [12]. pDCs were then suspended in RPMI 1640 medium
supplemented with 10% low-endotoxin fetal bovine serum (Sigma,
Saint Louis, MO, USA) and either immediately analyzed for antigen
expression, or cultured in 96-well U-bottom plates (Costar, Corning
Incorporated, Corning, NY) for functional assays (0.5  106 pDCs in
100 ll) [12]. In the latter case, cells were incubated in the presence
or the absence of optimal doses of IFNk3 (30 ng/ml, from R&D,
Minneapolis, MN, USA), and IL-3 (20 ng/ml, from Miltenyi) [12]
or their combination. In selected experiments, pDCs were preincu-
bated with 5 lg/ml aIFNAR (PBL Interferon Source, Piscataway, NJ,
USA); 5 lg/ml etanercept (ENBREL, Amgen, Thousand Oaks, CA,
USA), 2.5 mg/ml adalimumab (Abbott Laboratories, Abbott Park,
IL, USA) or their isotype control antibodies (Abs), before treatment
with stimuli.2.2. Flow cytometry analysis
To perform phenotypic studies, pDCs were first treated with 5%
human serum and then stained for 20 min at room T, using the
following mAbs: FITC anti-CD303 (Miltenyi), PE anti-IFNkR1
(BioLegend, San Diego, California, USA), PE-Cy7 anti-CD123 (BioLe-
gend), APC-Cy7 anti-HLA-DRa (BioLegend), as well as their related
isotype controls, as previously reported [12]. Sample fluorescence
was then measured by using an eight-color MACSQuant Analyzer
(Miltenyi), and data analysis performed by FlowJo software
Version 8.8.6 (TreeStar). Phenotypic analysis under the various
experimental conditions was performed in live cells identified as
singlet VybrantTM DyeCycleTM Violet-negative cells (Life Technolo-
gies, Carlsbad, CA, USA). The overall gating strategy for live cells
was performed as previously reported [12].Fig. 1. Effect of IFNk3 and/or IL-3 on the IFNk3R1 and IL-3Ra expression, as well as the su
and/or 20 ng/ml IL-3. Cells were harvested after 18 h and analyzed, by flow cytometry, fo
Bar graphs report the MFI means ± SEM (n = 7–15). MFI was calculated after subtrac
fluorescence. (C) pDCs were stained with the Vibrant DyeCycle, to assess their viability
performed as previously described [13].2.3. Gene expression studies
Total RNA was extracted from pDCs after lysis by RNeasy Mini
Kit (Qiagen, Venlo, Limburg, Netherlands). To completely remove
any possible contaminating DNA, an on-column DNase digestion
with the RNase-free DNase set (Qiagen) was performed during
total RNA isolation. Purified RNA was then reverse-transcribed into
cDNA and gene expression studies performed by reverse transcrip-
tion real-time PCR (RT-qPCR), as previously reported [12].2.4. Cytokine measurement
IFNa and TNFa production was measured in pDC-derived
supernatants using specific ELISA kits purchased from, respec-
tively, Mabtech (Nacka Strand, Sweden) and eBioscience. Detection
limits of these ELISAs were: 7 pg/ml for IFNa and 4 pg/ml for TNFa.2.5. Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis included
one-way or two-way analysis of variance (ANOVA), followed by
Tukey’s or Bonferroni’s post hoc test, respectively. Values of
P < 0.05 were considered statistically significant. Statistical analy-
sis was performed using Prism Version 6.0 software (GraphPad).3. Results
3.1. Both IFNk3 and IL-3 upregulate the expression of CD123/IL-3Ra
and IFNkR1 in human pDCs
Flow cytometry experiments revealed that both IFNk3 and IL-3,
in addition to increase the levels of CD123 (Fig. 1A) [12], also
upregulate the expression of IFNkR1 in human pDCs incubated
for 18 h (Fig. 1B), therefore suggesting that the two cytokines
may reciprocally influence responsiveness of pDCs to each other.
Since we have previously shown that either IFNk3 or IL-3 prolong
the viability of pDCs [12], we investigated whether they could pro-
mote a more potent pDC prosurvival effect when used in combina-
tion. As shown in Fig. 1C, that was not the case, because each
cytokine by itself was found to substantially trigger a maximal
increase of pDC survival. Similarly, neither CD123 (Fig. 1A), norrvival, by human pDCs. (A, B) pDCs were incubated with or without 30 ng/ml IFNk3
r CD123 (A) and IFNkR1 (B) expression in comparison to freshly isolated pDCs (T0).
ting the MFI given by the correspondent isotype control antibodies or the basal
under the same experimental conditions. Gating strategy to identify live pDCs was
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enhanced by IFNk3 and IL-3 used in combination.
3.2. IFNk3 and IL-3 synergistically induce the production of IFNa by
human pDCs
Subsequently, we analyzed the extracellular production of IFNa
by pDCs incubated with or without IFNk3 and/or IL-3 for up to
18 h. As shown in Fig. 2 (panel A displaying the values of all
individual donors; panel B the related means ± SEM), minimal
amounts of IFNa (less than 10 pg/ml) were detected in super-
natants from pDCs treated with either IFNk3 or IL-3, but not with
culture medium only. By contrast, a synergistic production of IFNaFig. 2. Production of IFNa by pDCs incubated with IL-3 and/or IFNk3 and involvement o
with or without 30 ng/ml IFNk3 and/or 20 ng/ml IL-3 for 5 and 18 h. Cell-free supernatant
results of all individual experiments for the displayed conditions, while panel (B) shows t
untreated pDCs. (C, D) pDCs were incubated for 5 and 18 h and evaluated for IFNa (C), IFIT
are depicted as mean normalized expression (MNE) units after RPL32 mRNA normaliza
(isotype control antibody, not shown) for 30 min and then incubated with IFNk3 and/or
mRNA expression exerted by aIFNaR antibodies (means ± SEM, n = 4). Under the sam
expression (data not shown). Significant variations: *P < 0.05; **P < 0.01; ***P < 0.001.was measured in supernatants harvested from pDCs incubated
with both IFNk3 and IL-3 for 18, but not 5 h (Fig. 2A and B), con-
comitantly with effects displayed also at gene expression level
(Fig. 2C). In these latter experiments, either IFNk3, or IL-3, were
found to modestly, but significantly, induce IFNamRNA accumula-
tion, at the 18 h time-point (Fig. 2C). Under the same experimental
conditions, pDCs cultured with R837/imiquimod, a classic activator
of these cells via TLR7 [19], produced remarkable levels of IFNa
already after 5 h (390 ± 205 pg/ml, n = 3), that even increase at
18 h (1821 ± 680 pg/ml, n = 4; data not shown). Interestingly, IL-3
was found to also upregulate the mRNA expression of various ISGs,
such as Interferon-Induced Protein with Tetratricopeptide Repeats
1 (IFIT1), ISG15 Ubiquitin-Like Modifier (ISG15) and Myxovirusf endogenous IFNa in mediating ISG mRNA expression. (A, B) pDCs were incubated
s were then collected and extracellular IFNameasured by ELISA. Panel (A) shows the
heir related means ± SEM (n = 5–16). No IFNawas measurable in supernatants from
1, ISG15 and MX1 (D) mRNA expression by RT-qPCR. Results (mean ± SEM, n = 5–14)
tion. (E) pDCs were incubated with or without 5 lg/ml of aIFNaR or mouse IgG2a
IL-3 for 18 h. Bar graphs show the percentage of inhibition of IFIT1, ISG15 and MX1
e experimental conditions, isotype control antibodies did not affect ISG mRNA
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trigger a similar effect already after 5 h (Fig. 2D). Notably, ISG
mRNA expression was synergistically upregulated in pDCs
cotreated with IFNk3 and IL-3 at both the 5 and 18 h time-
points, with the exception of IFIT1 mRNA at 5 h (Fig. 2D).
To clarify if, and to what extent, endogenous IFNa could be
responsible for the induction of ISG mRNA expression in pDCs
treated with IL-3 and/or IFNk3, we performed new experiments
using IFNaR neutralizing antibodies (Abs) [12]. As shown in
Fig. 2E, upregulation of IFIT1, ISG15 and MX1 mRNA expression
in pDCs treated with IL-3 for 18 h was largely blocked by the
aIFNaR Abs, suggesting a functional autocrine action by endoge-
nous IFNa. By contrast, ISG expression induced in pDCs either by
IFNk3 alone, or by IFNk3 plus IL-3, was only slightly affected by
the aIFNaR Abs (Fig. 2E), indicating a direct effect of IFNk3 in
triggering the expression of IFIT1, ISG15 and MX1 mRNAs. Taken
together, data demonstrate that IL-3 induces the production of
small, but biologicaly active amounts of IFNa from human pDCs,
which in turn autocrinally promotes the expression of ISG
mRNAs. Data also show that IFNk3 plus IL-3 synergize in induc-
ing the producton of IFNa, as well as the expression of ISG
mRNA: the latter phenomenon, however, occurs independently
from endogenous IFNa.Fig. 3. Synergistic production of TNFa by pDCs incubated with IL-3 plus IFNk3. (A–C) pD
18 h, to analyze their TNFa production (A and B) or TNFa gene expression (panel C). (A) R
(n = 5–17). (C) TNFa mRNA expression in IFNk3 and/or IL-3-treated pDCs. Gene expressio
units after RPL32 mRNA normalization. (D) pDCs were pretreated for 30 min with or with
or IL-3for 18 h. Bar graphs show the percentages of inhibition on TNFa production (n = 3
control antibodies did not affect TNFa production (data not shown). Significant variatio3.3. IFNk3 and IL-3 synergistically induce the production of TNFa by
human pDCs independently from IFNa
Measurement of TNFa in the same pDC-derived supernatants
confirmed [12] that IFNk3 induces the production of very
low, but detectable, extracellular levels of the cytokine
(Fig. 3A and B). Similarly, IL-3 confirmed [19] to trigger a remark-
able production of TNFa by pDCs already after 5 h of incubation
(Fig. 3A and B). Interestingly, the amounts of TNFa detected in
supernatants from IFNk3 plus IL-3-treated pDCs were significantly
higher than those from IL-3-treated pDCs, but only at the 18 h
time-point (Fig. 3A and B), consistent with findings at the TNFa
mRNA level (Fig. 3C). Expression of TNFa mRNA in pDCs treated
with IL-3 or IFNk3 alone was instead maximal after 5 and 18 h,
respectively (Fig. 3C). Given that endogenous IFNa was previously
shown to be involved in supporting TNFa production in IL-3 plus
CpG-stimulated pDCs [20], we investigated its role by incubating
IFNk3- and/or IL-3-treated pDCs in the presence of aIFNaR Abs
for 18 h. As shown in Fig. 3D, the production of TNFa by IFNk3
and/or IL-3-treated pDCs was minimally influenced by the
presence of aIFNaR Abs, suggesting that in our conditions
endogenously produced IFNa is substantially dispensable for the
generation of TNFa, independently from its yields.Cs were incubated with or without 30 ng/ml IFNk3 and/or 20 ng/ml IL-3 for 5 and
esults from all individual measurements by ELISA. (B) Means ± SEM of samples in A
n data (mean ± SEM, n = 8–14) are depicted as mean normalized expression (MNE)
out 5 lg/ml aIFNaR or mouse IgG2a (not shown) and then incubated with IFNk3 and/
–5) exerted by aIFNaR antibodies. Under the same experimental conditions, isotype
ns: **P < 0.01; ***P < 0.001.
128 G. Finotti et al. / Cytokine 86 (2016) 124–1313.4. Endogenous TNFa is required for IFNa production by IFNk3- and/
or IL-3-treated pDCs
Because it has been previously shown that, in primary or syn-
ovial macrophages from patients with rheumatoid arthritis, TNFa
may function as an endogenus inducer of type I IFN production
[21,22], we investigated whether the same could occur under
our experimental conditions. As shown in Fig. 4, etanercept
(ETA), a TNFa blocker [23], potently inhibited both IFNa mRNA
expression (Fig. 4A) and IFNa production (Fig. 4B) in pDCs trea-
ted with IFNk3 plus IL-3 for 18 h. It was not possible to precisely
quantify the effect of ETA on the production of IFNa by IFNk3-
or IL-3-treated pDCs due to the scarce amounts of IFNa pro-
duced. However, expression of IFNa mRNA was almost com-
pletely abrogated by ETA in pDCs treated with either IFNk3 or
IL-3 (data not shown). Nonetheless, ETA almost completely
blocked IFIT1 and ISG15 (Fig. 4C) mRNA expression in pDCs trea-
ted with IFNk3 plus IL-3, consistent with the results shown in
Fig. 4A. ETA also diminished the expression of IFIT1 and ISG15
mRNA induced not only by IFNk3, but also by IL-3 alone, in
the latter case more effectively (Fig. 4C). Finally, TNFa exoge-
nously added to pDC cultures was found to directly induce either
the production of IFNa (Fig. 4D), at levels similar to IFNk3 or IL-
3 (see Fig. 2A), or a rapid expression of ISG15 mRNA (Fig. 4E).
Altogether, data demonstrate that the synergistic production of
IFNa by pDCs incubated with IFNk3 plus IL-3 is mainly mediated
by endogenous TNFa, which is synergistically induced by the
two stimuli used in combination.Fig. 4. Role of endogenous TNFa in mediating the production of IFNa and the expression
or without 5 lg/ml ETA or human IgG1 (isotype control antibodies) for 30 min, and th
inhibition on IFNamRNA expression (A) and IFNa production (B) (means ± SEM, n = 3–4)
did not affect IFNa production or mRNA expression (data not shown). (C) pDCs were pre
18 h. The percentage of inhibition on IFIT1 and ISG15 mRNA expression is reported (mean
for 5 and 18 h, to measure their capacity to produce IFNa (values expressed as mean ± S
Gene expression data (mean ± SEM, n = 4) are depicted as mean normalized expression4. Discussion
In this study, we investigated whether IFNk3 and IL-3 recipro-
cally influence their capacity to activate various functions of
human pDCs, given that IFNk3 increases the expression of IL-
3Ra/CD123 [12], while IL-3 augments the expression of IFNkR1.
Accordingly, we found that pDCs incubated for 18 h with IFNk3
plus IL-3 produce IFNa at levels synergistically higher than pDCs
treated with either IFNk3 or IL-3 alone. Even though we further
show that IFNa mRNA expression substantially correlates with
IFNa production, we did not investigate the intracellular signaling
pathways whereby IFNk3 plus IL-3 synergistically trigger the tran-
scription of IFNa. In such regards, it might be possible that IFNk3
positively regulates the pathways triggered in IL-3-treated pDCs
and involved in IFNa production, namely the PI3K- and MAPK-
signaling cascades [24,25]. It cannot be excluded that the two
cytokines might act either at the post-transcriptional level, for
instance prolonging IFNamRNA stability or amplifying IFNamRNA
translation, or at the chromatin level, favoring an increase accessi-
bility of the transcriptional machinery at the IFNa locus. Whatever
the case is, since both IFNk3 and IL-3 alone were found to actively
induce IFNa mRNA expression and production in pDCs, we would
favor the notion that the different signaling pathways triggered by
the two cytokines ultimately converge to synergistically increase
IFNa gene transcription and protein production.
Since we uncovered that the mRNA expression of ISGs,
including IFIT1, ISG15 and MX1 was also synergistically increased
in pDCs treated with IFNk3 plus IL-3, we asked whetherof ISG mRNAs in pDCs treated with IL-3 plus IFNk3. (A, B) pDCs were pretreated with
en incubated with IL-3 plus IFNk3 for 18 h. Bar graphs shows the percentage of
exerted by ETA. Under the same experimental conditions, isotype control antibodies
treated with or without 5 lg/ml ETA and then incubated with IFNk3 and/or IL-3 for
s ± SEM, n = 3). (D) pDCs were cultured in the presence or absence of 10 ng/ml TNFa,
EM, n = 4). (E) IFIT1 mRNA expression in pDCs treated with 10 ng/ml TNFa for 3 h.
(MNE) units after RPL32 mRNA normalization.
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nomenon. Unexpectedly, IFNaR neutralizing antibodies only
slightly decreased ISG mRNA expression in IFNk3 plus IL-3-
treated pDCs. Such a minor role of endogenous IFNa in inducing
ISG mRNAs could be explained by the fact that it is IFNk3 itself that
directly upregulates ISG genes, given that IFNk3 triggers signaling
pathways similar to those activated by type I IFN [4]. Accordingly,
IFNaR blocking experiments did not influence ISG mRNA expres-
sion observed in pDCs incubated with IFNk3 alone. By contrast,
we found that, just by itself, IL-3 upregulates in pDCs ISG mRNA
expression at levels comparable to those induced by IFNk3 alone,
and, surprisingly, in a fashion totally dependent on endogenous
IFNa. Altogether, data suggest that the synergistic expression of
ISG mRNAs in pDCs incubated with IFNk3 plus IL-3 derives, in part,
from the a direct effect of IFNk3, and, in part, from an action trig-
gered by IL-3 and mediated via endogenous IFNa.
It has been previously shown that pDCs incubated with IL-3
produce variable amounts of TNFa [18,19]. Moreover, pDCs incu-
bated with RNA-containing immune complexes (IC) in the pres-
ence of GM-CSF, a cytokine that shares with IL-3 the b-chain
receptor for signaling, were found to produce synergistic amounts
of both IFNa and TNFa as compared to RNA-IC alone [15]. Further-
more, we previously found that even IFNk3 induces the production
of low, but biologically active, levels of TNFa by human pDCs [12].
All these observations prompted us to subsequently analyze the
production of TNFa by pDCs treated with IFNk3 and/or IL-3. As a
result, we found that IFNk3 plus IL-3 induce a synergistic induction
of both TNFa mRNA expression and TNFa production as compared
to those induced by IL-3/IFNk3 alone, which was detectable after
18 h and maintained up to 42 h of culture (our unpublished obser-
vations). In such regard, it is well known that the induction of TNFa
mRNA expression usually depends on stimuli able to activate
NFjB- and/or MAPK-dependent pathways [26,27], IL-3 being one
of them [13]. Similarly, and as already proved for type I IFNs
[28], also IFNk3 is able to activate NFjB- and/or MAPK-
dependent signaling pathways [29,30]. Thus, to explain how the
synergistic production of TNFa by IFNk3 plus IL-3-treated pDCs
occurs at molecular/biochemical levels, we would speculate that
IL-3 is mostly responsible to activate NF-jB/MAPK pathways,
while IFNk3 simply potentiates such IL-3-triggered signaling, in
turn leading to a stronger TNFa mRNA expression and protein
production. However, this speculation needs to be formally
ascertained.
Subsequently, we explored whether, in IL-3-treated pDCs,
endogenous IFNa could have some role in inducing TNFa produc-
tion, similarly to its action on ISG mRNA expression. As putative
control, we used pDCs treated with IFNk3 plus IL-3 as, under this
condition, IFNa production is synergistically increased. However,
IFNaR neutralizing antibodies had only a minor, or even no, effect
on the production of TNFa secreted by pDCs treated either by IL-3
alone, or by IFNk3 plus IL-3, suggesting that, independently of its
yields, endogenous IFNa is not required for the production of TNFa.
Conversely, experiments using different TNFa inhibitors, namely
etanercept and adalimumab (our unpublished observations)
allowed us to uncover that the production of IFNa by IFNk3 plus
IL-3-treated pDCs is mostly driven by endogenous TNFa. Similarly,
we found that also the expression of ISGs in IFNk3 plus IL-3-treated
pDCs is mostly driven by endogenous TNFa. Thus, data suggest
that, in IFNk3 plus IL-3-stimulated pDCs, endogenous TNFa is
responsible for both the synergistic production of IFNa and ISG
mRNA expression. Interestingly, we found that ETA almost com-
pletely abrogates the expression of both IFNa and ISG mRNAs even
in pDCs treated with either IFNk3 or IL-3. However, it was not pos-
sible to precisely quantify the effect of TNFa inhibitors on the pro-
duction of IFNa by either IFNk3-, or IL-3-treated pDCs due to the
scarce cytokine levels. In any case, ETA almost completely blockedIFIT1, ISG15 and MX1 mRNA expression in pDCs treated with IL-3,
consistent with an inhibition on IFNa-dependent effects. A down-
modulation of ISG expression by ETA was detected also in IFNk3-
treated pDCs, yet an effect IFNa-independent as, under the same
experimental conditions, aIFNaR antibodies were ineffective.
Although these results need to be carefully interpreted, it is possi-
ble that endogenous TNFa directly contributes to the transcrip-
tional control of ISGs via NF-jB- and/or MAPK-dependent
pathways, as also proposed by the literature [31–33]. Moreover,
exogenous TNFa was found to directly induce both the production
of IFNa (in low amounts) and the expression of ISG15 mRNA in
pDCs, confirming their responsiveness to TNFa.
In sum, in this work we report that pDCs incubated with
IFNk3 plus IL-3 synergize in triggering the production of remark-
able amounts of both IFNa and TNFa. We also demonstrate that
the production of IFNa by IFNk3 plus IL-3-treated pDCs is mostly
dependent on endogenously produced TNFa. Along with a direct
effect of IFNk3, endogenously produced TNFa also controls ISG
mRNA expression, either directly, or via IFNa. These results are
consistent with a crucial role of pDC-derived TNFa in autocrin-
ally amplifying the production of cytokines, as previously
reported in the case of CXCL10 production by pDCs [12]. More-
over, data suggest that IFNk3 and IL-3 collaborate to promote
discrete functional responses of human pDCs at maximal levels.
Under this perspective, data point for an important role of IL-3,
likely secreted by infiltrating T cells at the sites of infection
[13,15], in enhancing pDC responses. Moreover, even IL-3 pro-
duced by endothelial cells [34] might have a role in potentiating
or influencing pDC activities during their transmigration into the
site of infection, lymph nodes and/or tumors [35,36]. Interest-
ingly, it has been recently shown that, during sepsis, a clinically
serious systemic inflammation in which type I IFNs play critical
roles [37], IL-3 is produced in the spleen, mostly by activated B
and T lymphocytes [38]. In this context, IFNa/k-enhanced B cell
activation results in increased cytokine and Ig production during
TLR7 challenge [39]. In addition, a strict pDC-B cell crosstalk
exists as B cells enhance IFNa, and possibly IFNks, production
by pDCs via cell–cell contact or soluble factors [40]. For these
reasons, it is plausible that, not only in sepsis, but also in other
autoimmune diseases, B cells could promote and amplify, via
their production of IL-3, the activation and function of pDCs. A
potential collaboration between IFNk3 and IL-3 may even occur
in tumors in which pDCs, IFNks and also IL-3 are detectable
[3,16,36,41]. Accordingly, IL-3 and/or IFNk3 could favor pDC
antitumoral activities [11].
Finally, it is worth mentioning that IL-3 is often used to main-
tain pDC survival in culture [20,42–44], particularly in experiments
in which researchers investigate the effect of a given stimulus on
pDCs. However, the potential contribution of IL-3 in influencing
the final results is often ignored [43,45]. Our data, highlighting that
IL-3 may induce a number of responses that might sum up to those
exerted by the stimulus under investigation (in this case IFNk3),
suggest that the potential contribution of IL-3 need to be always
taken into consideration for a correct interpretation of the final
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